Transcend Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Transcend Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$562K	Sell	901 -125	-12%	-$85.1K	0.04%	414
2026 Q1	$793K	Buy	1,026 +51	+5%	+$39K	0.06%	283
2025 Q4	$753K	Buy	975 +296	+44%	+$201K	0.06%	285
2025 Q3	$382K	Buy	+679	New	+$384K	0.03%	451
2023 Q1	–	Sell	-418	Closed	-$302K	–	516
2022 Q4	$302K	Buy	418 +114	+38%	+$84.1K	0.03%	361
2022 Q3	$209K	Buy	+304	New	+$191K	0.02%	439
2020 Q2	–	Sell	-467	Closed	-$239K	–	179
2020 Q1	$239K	Buy	+467	New	+$193K	0.07%	180

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Transcend Capital Advisors's REGN Position: Q2 2026 in Review

Transcend Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $85.1K and leaving 901 shares worth $562K. The position accounts for 0.04% of the portfolio, ranked #414.

Transcend Capital Advisors first reported a position in REGN in Q1 2020 and has held it in 7 quarters since. The position peaked at $793K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Transcend Capital Advisors held 901 shares of Regeneron Pharmaceuticals worth $562K as of Q2 2026.
Transcend Capital Advisors sold 125 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $85.1K.
Regeneron Pharmaceuticals made up 0.04% of Transcend Capital Advisors's portfolio in Q2 2026, its #414 holding.
Transcend Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 7 quarters since.
Transcend Capital Advisors's Regeneron Pharmaceuticals position peaked at $793K in Q1 2026.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.